

DIAGNOSING BLADDER CANCER EARLIER:

CADETSM BRAF MUTATION DETECTION ASSAY





BLADDER CANCER OVERVIEW

 Canine transitional cell carcinoma (TCC), also known as urothelial carcinoma (UC), is a malignant tumor that can affect the bladder, urethra, and kidneys of male and female dogs and also the prostate of males

Each year in the US, an estimated 50,000 dogs are

diagnosed with TCC/UC





BLADDER CANCER INCIDENCE RATES

- Most cases are diagnosed in the bladder and at an advanced stage of disease
- More than 90% of cases occur in dogs age 6 years and older
- TCC/UC shows higher incidence rates in following breeds:

- American Eskimo Dog
- Australian Cattle Dog,
- Australian Shepherd
- Beagle
- Bichon Frise
- Border Collie,
- Jack/Parson Russell Terrier
- Lhasa Apso
- Rat Terrier
- Scottish Terrier
- Shetland Sheepdog
- West Highland White Terrier
- Wire Fox Terrier








BLADDER CANCER TRADITIONAL DIAGNOSIS

- Repeated visits to the veterinarian
 - Urine culture at the start of physical symptoms
 - Administration of antibiotics and/or anti-inflammatory medications over several months
 - Treatment of the symptoms not the disease

By the time mass is detected, danger of tumor spreading to other parts of body



The point at which the dog shows physical symptoms depends on location of tumor

Blood in urine/ straining during urination.

administered

tumor continues to spread

Rx represcribed

tumor continues to spread Cystoscopy performed to detect mass

* Scenario example only. Not indicative of all cases.





A NEW OPPORTUNITY FOR EARLIER DETECTION

- A single mutation in a gene called BRAF is present in 85% of confirmed canine TCC/UC cases
 - Not found in the urine of healthy dogs or dogs that have nonmalignant bladder polyps, inflammation or cystitis
 - Can be detected in cells shed in the urine of a dog well before symptoms of the disease develop, allowing for early intervention with the most appropriate treatment








CADETSM BRAF MUTATION DETECTION ASSAY

HOW IT WORKS

Detects the presence of fewer than 10 tumor cells (with the BRAF mutation) shed into the urine presence of a canine TCC/UC








CADETSM BRAF MUTATION DETECTION ASSAY

BENEFITS

- Most sensitive means to detect the presence of a canine TCC/UC
 - Detects the presence of TCC/UC up to 4 months before any signs of clinical disease become evident in a dog
 - Allows treatment for the cancer to begin sooner than waiting for repeated use of antibacterial/anti-inflammatory medications
 - Treat cancer sooner to provide improved quality and length of life
 - Provides convenient, fast, reliable, and non-invasive detection
 - Quick returns from the lab
 - No clinic fees
 - Saved time waiting for alternative treatment to symptoms








BLADDER CANCER EARLIER DETECTION

- Starting at 6 years, submit urine samples from your dog at four month intervals for analysis
 - Non-invasive urine collection done at home
 - Regain precious time for your dog by screening his/her urine for the presence of a TCC/UC at the earliest states of development



* Scenario example only. Not indicative of all cases.





CADETSM BRAF MUTATION DETECTION ASSAY

ANNUAL SUBSCRIPTION

- All materials to collect and package 3 urine samples, sent direct to your door
- FREE shipping to send all 3 samples back to the lab for testing
- 3. Fast results in under 2 weeks from receipt of urine
- 4. No clinic fees







CADETSM PROGRAM MISSION



- Sentinel Biomedical and the American Kennel Club are working together to offer a new line of genetic tests for early Canine CAncer DETection (CADET[™])
 - Investigate the genetic and environmental factors associated with transitional cell/urothelial carcinomas of the bladder and prostate
 - Each subscriber will have the option to be part of a large nationwide research study:
 - Access to updates of the research program to learn how their dog(s) have contributed
 - Provide valuable data to help your breed and other breeds diagnosed with these cancers
 - Study environmental implication for human cancer patients



